Acrobiosystems Co

Acrobiosystems Co EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 65.72. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -119.25 — a change of -155.10% (higher).

EV/FCF

65.72

YoY

-155.10%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Acrobiosystems Co is 2025 65.72 . EV/FCF (Enterprise Value to Free Cash Flow) of Acrobiosystems Co was 2024 -119.25 . It decreases by -155.10% higher compared to the previous year.

The Acrobiosystems Co EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-4,279.99 CNY
Jan 1, 2019
954.91 CNY
Jan 1, 2020
120.78 CNY
Jan 1, 2021
128.95 CNY
Jan 1, 2022
-119.92 CNY
Jan 1, 2023
-562.91 CNY
Jan 1, 2024
-119.25 CNY
Jan 1, 2025
65.72 CNY
The Acrobiosystems Co EV/FCF history
YEAREV/FCFYoY
65.72-155.10%
-119.25-78.81%
-562.91+369.40%
-119.92-193.00%
128.95+6.76%
120.78-87.35%
954.91-122.31%
-4,279.99—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

EV/FCF (Enterprise Value to Free Cash Flow) of Acrobiosystems Co is 65.72 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Acrobiosystems Co changed from -119.25 to 65.72, representing a -155.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Acrobiosystems Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co